SABSW
SAB Biotherapeutics, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0477
- Prev close
- 0.0043
- Mkt cap
- 10.51K
- Vol
- 581.55K
- Avg vol
- 0
- EPS
- 0.292
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0126
- Forward P/E
- 0.00
- Beta
- 0.64
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.26
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.02
- EPS (TTM)
- 0.292
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.51M
- Revenue growth
- 0.00%
- Free cash flow
- -26.31M
- Total cash
- 30.40M
- Total debt
- 4.52M
- Return on equity
- -174.73%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sabbiotherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on SABSW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HB Wealth Management, LLC | 5.39% | 310,000 | 23.90K | Sep 29, 2024 |
| Morgan Stanley | 2.55% | 146,439 | 11.29K | Sep 29, 2024 |
| Yakira Capital Management, Inc. | 1.89% | 108,485 | 8.36K | Sep 29, 2024 |
| Walleye Capital LLC | 0.40% | 23,258 | 1.79K | Sep 29, 2024 |
| Wolverine Asset Management, LLC | 0.27% | 15,519 | 1.20K | Sep 29, 2024 |
| Walleye Trading LLC | 0.27% | 15,505 | 1.20K | Sep 29, 2024 |